CD19 and systemic lupus erythematosus: Beyond NMOSD, CD19-directed therapy is being actively explored in several antibody-mediated autoimmune diseases, including systemic lupus erythematosus, ANCA-associated vasculitis, IgG4-related disease, and myasthenia gravis [117].